You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華邦健康(002004.SZ):獲得化學藥品鹽酸莫西沙星片的藥品註冊批件
格隆匯 01-07 17:37

格隆匯1月7日丨華邦健康(002004.SZ)公佈,公司全資子公司重慶華邦製藥有限公司(“華邦製藥”)於近日獲得國家藥品監督管理局核准簽發的化學藥品鹽酸莫西沙星片的《藥品註冊批件》。

鹽酸莫西沙星屬於第四代廣譜氟喹諾酮類抗感染藥物,與前三代抗感染藥物相比,對革蘭氏陽性菌、革蘭氏陰性菌、厭氧菌等常見病原菌的抗菌活性更強,同時具有安全性高、耐藥率低的優勢。鹽酸莫西沙星主要用於治療患有上呼吸道和下呼吸道感染(如社區獲得性肺炎、急性鼻竇炎、慢性支氣管炎急性發作)的成人,以及皮膚和軟組織感染。

鹽酸莫西沙星片為《國家基本醫療保險、工傷保險和生育保險目錄(2019年版)》乙類藥品,華邦製藥鹽酸莫西沙星片已納入《中國上市藥品目錄集》(按化學藥品新註冊分類批准的仿製藥)。

鹽酸莫西沙星片藥品註冊批件的取得進一步擴展了公司產品治療領域,對進一步優化公司產品結構有着積極的意義,隨着該產品市場佔有率的逐步增加,對公司業績的提升將產生積極影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account